$GEGR Announces Asset Exchange for Swiss Stem Cell
Post# of 42117
(Total Views: 160)
Posted On: 03/08/2022 8:40:53 AM
$GEGR Announces Asset Exchange for Swiss Stem Cells Biotech SA (SSCB) and Re-You Suisse SA
Salt Lake City, Utah--(Newsfile Corp. - March 4, 2022) - Gaensel Energy Group, Inc., (OTC Pink: GEGR) ("Gaensel" or the "Company"
, a diversified holding company announces a corporate update.
As of March 1, 2022, the Company has agreed to terminate 100% of its interest in Swiss Stem Cells Biotech, SA, (SSCB). As of March 1, 2022, the Company has agreed to terminate 100% of its interest Re-You Suisse SA. The termination of these two interests was requested due to financial issues relating to US based ownership of Switzerland based companies. The Company, in consideration of these actions, has been authorized and empowered to establish Stem Cells Biotech in the United States which will have the exclusive rights in North and South America, including Canada. The Company, in consideration of these actions, has been authorized and empowered to establish Re-You SA the United States which will have the exclusive rights in North and South America, including Canada. The company will retain 50% of the ownership of the two United States including the technological and intellectual property.
The Company will be providing additional updates the week of March 7th , including our filing of our Annual Report and information on new corporate transactions.
About Gaensel Energy Group, Inc. (OTC Pink: GEGR):
Gaensel Energy Group asset base currently consists of proven companies in Biotech, Commodities, Health, Beauty - Fashion, Green and Renewable Energy, and Technology. The management teams for each of these divisions are actively seeking similar partners in each space for expansion and additional acquisitions. We have been listed on the United States OTC Markets since 2002 and the Company is current.
Gaensel Energy Group, Inc.
57 West 200 South
Suite 300
Salt Lake City, UT 84101
admin@gegrgroup.com
Phone: +1 518-567-3649
https://www.gegrgroup.com
https://twitter.com/gegrgroup
https://finance.yahoo.com/news/gaensel-energy...00283.html
Salt Lake City, Utah--(Newsfile Corp. - March 4, 2022) - Gaensel Energy Group, Inc., (OTC Pink: GEGR) ("Gaensel" or the "Company"
, a diversified holding company announces a corporate update. As of March 1, 2022, the Company has agreed to terminate 100% of its interest in Swiss Stem Cells Biotech, SA, (SSCB). As of March 1, 2022, the Company has agreed to terminate 100% of its interest Re-You Suisse SA. The termination of these two interests was requested due to financial issues relating to US based ownership of Switzerland based companies. The Company, in consideration of these actions, has been authorized and empowered to establish Stem Cells Biotech in the United States which will have the exclusive rights in North and South America, including Canada. The Company, in consideration of these actions, has been authorized and empowered to establish Re-You SA the United States which will have the exclusive rights in North and South America, including Canada. The company will retain 50% of the ownership of the two United States including the technological and intellectual property.
The Company will be providing additional updates the week of March 7th , including our filing of our Annual Report and information on new corporate transactions.
About Gaensel Energy Group, Inc. (OTC Pink: GEGR):
Gaensel Energy Group asset base currently consists of proven companies in Biotech, Commodities, Health, Beauty - Fashion, Green and Renewable Energy, and Technology. The management teams for each of these divisions are actively seeking similar partners in each space for expansion and additional acquisitions. We have been listed on the United States OTC Markets since 2002 and the Company is current.
Gaensel Energy Group, Inc.
57 West 200 South
Suite 300
Salt Lake City, UT 84101
admin@gegrgroup.com
Phone: +1 518-567-3649
https://www.gegrgroup.com
https://twitter.com/gegrgroup
https://finance.yahoo.com/news/gaensel-energy...00283.html
(0)
(0)Scroll down for more posts ▼